Synapse - Genitourinary Oncology Service

Search Within

Genitourinary Oncology Service

Results (5695)

Novel circulating proteins, single nucleotide polymorphisms (SNPs), and molecular tumor markers as potential biomarkers of sunitinib efficacy in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC)

Meeting Abstract

Motzer, R. J.; Hutson, T. E.; Hudes, G. R.; Figlin, R. A.; Martini, J.; English, P. A.; Wood, L.; Huang, X.; Valota, O.; Williams, J. A.
Annals of Oncology (2012)

Fulltext@MSK | Save

Axitinib vs sorafenib for advanced renal cell carcinoma: Phase III overall survival results and analysis of prognostic factors

Meeting Abstract

Motzer, R. J.; Escudier, B.; Tomczak, P.; Negrier, S.; Gore, M. E.; Tarazi, J.; Hariharan, S.; Rosbrook, B.; Kim, S.; Rini, B. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

Phase I trial of ASG-5ME in metastatic castration resistant prostate cancer (CRPC)

Meeting Abstract

Morris, M.; Bruce, J.; Reyno, L.; Anand, B.; Hartford, A.; Jelaca-Maxwell, K.; Lackey, J.; Eisenberger, M.
Annals of Oncology (2012)

Fulltext@MSK | Save

A phase IB clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Meeting Abstract

Molina, A. M.; Hutson, T. E.; Larkin, J.; Gold, A.; Andresen, C.; Wood, K.; Motzer, R. J.; Michaelson, M. D.
Annals of Oncology (2012)

Fulltext@MSK | Save

Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study

Meeting Abstract

Fizazi, K.; Scher, H. I.; Saad, F.; Sternberg, C. N.; Miller, K.; Mulders, P.; Chi, K.; Basch, E.; Hirmand, M.; de Bono, J. S.
Annals of Oncology (2012)

Fulltext@MSK | Save

Detailed comparison of the safety of tivozanib versus sorafenib in patients with advanced/metastatic renal cell carcinoma (mRCC) from a phase 3 trial

Meeting Abstract

Eisen, T. Q. G.; Sternberg, C. N.; Tomczak, P.; Harza, M.; Jinga, V.; Esteves, B.; Motzer, R. J.
Annals of Oncology (2012)

Fulltext@MSK | Save

Comparative assessment of sunitinib-associated adverse events (AES) as potential biomarkers of efficacy in metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Donskov, F.; Michaelson, M. D.; Puzanov, I.; Davis, M. P.; Bjarnason, G. A.; Motzer, R. J.; Lin, X.; Cohen, D. P.; Wiltshire, R.; Rini, B. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

Cabozantinib (XL184) at 40 mg in patients with metastatic castration resistant prostate cancer (mCRPC): Results of a phase 2 non-randomized expansion cohort (NRE)

Meeting Abstract

de Bono, J. S.; Smith, M. R.; Rathkopf, D.; Corn, P. G.; Mukherji, D.; Harzstark, A. L.; Sartor, O. A.; Smith, D. C.; Tunariu, N.; Sweeney, C.
Annals of Oncology (2012)

Fulltext@MSK | Save

The analytical validation of prostate specific mRNA detection in whole blood by reverse transcription-polymerase chain reaction (RT-PCR) as a prognostic biomarker for patients with castration-resistant prostate cancer (CRPC)

Meeting Abstract

Danila, D.; Anand, A.; Heller, G.; Wan, M.; Zehnder, M.; Khanin, R.; Schultz, N.; Fleisher, M.; Lilja, H.; Scher, H. I.
Annals of Oncology (2012)

Fulltext@MSK | Save

The impact of abiraterone acetate (AA) therapy on patient-reported pain and functional status in chemotherapy-naive patients with progressive, metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Basch, E.; Ryan, C. J.; Kheoh, T.; Fizazi, K.; Logothetis, C. J.; Rathkopf, D. E.; Smith, M. R.; Mainwaring, P. N.; Hao, Y.; Griffin, T.; more...
Annals of Oncology (2012)

Fulltext@MSK | Save